CN109641963A - 癌症的联合治疗 - Google Patents

癌症的联合治疗 Download PDF

Info

Publication number
CN109641963A
CN109641963A CN201780049391.8A CN201780049391A CN109641963A CN 109641963 A CN109641963 A CN 109641963A CN 201780049391 A CN201780049391 A CN 201780049391A CN 109641963 A CN109641963 A CN 109641963A
Authority
CN
China
Prior art keywords
cancer
tgf
antibody
protein
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780049391.8A
Other languages
English (en)
Chinese (zh)
Inventor
劳健明
兰燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN109641963A publication Critical patent/CN109641963A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780049391.8A 2016-08-12 2017-08-11 癌症的联合治疗 Pending CN109641963A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374621P 2016-08-12 2016-08-12
US62/374,621 2016-08-12
PCT/EP2017/070513 WO2018029367A1 (en) 2016-08-12 2017-08-11 Combination therapy for cancer

Publications (1)

Publication Number Publication Date
CN109641963A true CN109641963A (zh) 2019-04-16

Family

ID=59686928

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780049391.8A Pending CN109641963A (zh) 2016-08-12 2017-08-11 癌症的联合治疗

Country Status (16)

Country Link
US (2) US20180118832A1 (enExample)
EP (1) EP3497130B1 (enExample)
JP (1) JP7573365B2 (enExample)
KR (3) KR20250028537A (enExample)
CN (1) CN109641963A (enExample)
AU (2) AU2017310027A1 (enExample)
BR (1) BR112019001818A2 (enExample)
CA (1) CA3031168A1 (enExample)
CL (1) CL2019000277A1 (enExample)
ES (1) ES2905663T3 (enExample)
IL (1) IL264730B2 (enExample)
MX (1) MX2019001503A (enExample)
PH (1) PH12019500270A1 (enExample)
RU (1) RU2019106663A (enExample)
SG (1) SG11201901126UA (enExample)
WO (1) WO2018029367A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020248926A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗PDL1和TGFβ的双功能融合蛋白及其用途
WO2021043229A1 (zh) * 2019-09-05 2021-03-11 复旦大学 靶向肿瘤的重组双功能融合蛋白及其应用
WO2021063350A1 (zh) * 2019-09-30 2021-04-08 和铂医药(苏州)有限公司 一种融合蛋白及其应用
WO2021115456A1 (en) * 2019-12-11 2021-06-17 Wuxi Biologics (Shanghai) Co., Ltd. BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ
WO2022063193A1 (zh) * 2020-09-24 2022-03-31 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CN115461362A (zh) * 2020-04-14 2022-12-09 葛兰素史密斯克莱知识产权发展有限公司 基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
SI3628049T1 (sl) 2017-05-04 2023-10-30 Acceleron Pharma Inc. Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba
US20210015857A1 (en) * 2018-03-23 2021-01-21 The University Of Western Australia Method for immunotherapy drug treatment
JP2021522298A (ja) * 2018-05-04 2021-08-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌治療のためのＰＤ−１／ＰＤ−Ｌ１、ＴＧＦβおよびＤＮＡ−ＰＫの同時阻害
CN112118858A (zh) * 2018-05-15 2020-12-22 默克专利有限公司 用于未经治疗对象中癌症治疗的靶向tgf-β抑制的给药方案
SG11202012426WA (en) * 2018-06-13 2021-01-28 Merck Patent Gmbh Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
BR112020026902A2 (pt) * 2018-07-02 2021-03-30 Merck Patent Gmbh Terapia combinada com inibição direcionada de tgf-b para o tratamento de câncer de pulmão de células não pequenas avançado
SG11202100208VA (en) * 2018-07-09 2021-02-25 Precigen Inc Fusion constructs and methods of using thereof
CN112969714B (zh) * 2018-11-30 2022-11-22 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
MX2021009175A (es) 2019-01-30 2021-09-14 Scholar Rock Inc Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
EP3693974A1 (en) * 2019-02-07 2020-08-12 Koninklijke Philips N.V. Identifying responsiveness to radio-immuno combination therapy
EP3990116A1 (en) * 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
BR112022004563A2 (pt) * 2019-09-12 2022-06-07 Sirnaomics Inc Coliberação de sirna tgf-ß e sirna pdl1 para tratar câncer
WO2021078123A1 (en) 2019-10-21 2021-04-29 Nanjing Leads Biolabs Co., Ltd. RECOMBINANT PROTEIN TARGETING PD-1 AND TGFβ
WO2021084124A1 (en) 2019-11-01 2021-05-06 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
KR20220097443A (ko) * 2019-11-05 2022-07-07 메르크 파텐트 게엠베하 암의 치료를 위한 PD-1, TGFβ 및 TIGIT의 조합 억제
EP3838260A1 (en) 2019-12-20 2021-06-23 Ares Trading S.A. Igg:tgf rii fusion protein composition
CN115135302A (zh) 2019-12-20 2022-09-30 阿雷斯贸易股份有限公司 IgG:TGFβRII融合蛋白组合物
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
MX2022008609A (es) 2020-01-11 2022-11-10 Scholar Rock Inc Inhibidores de tgf¿ y uso de los mismos.
EP4093779A4 (en) * 2020-02-25 2024-03-06 Wuxi Biologics Ireland Limited BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
WO2022011256A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
WO2022017487A1 (zh) * 2020-07-24 2022-01-27 迈威(上海)生物科技股份有限公司 TGF-β RII突变体及其融合蛋白
AU2021370991A1 (en) 2020-11-02 2023-06-22 Ares Trading S.A. Combination treatment of cancer
CA3196557A1 (en) 2020-11-02 2022-05-05 Ada SALA-HOJMAN Combination treatment of cancer
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AU2022270880A1 (en) 2021-05-03 2023-09-28 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
CA3221411A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
JP2024520764A (ja) 2021-06-07 2024-05-24 アレス トレーディング ソシエテ アノニム 癌の組み合わせ処置
GB202215997D0 (en) * 2022-10-28 2022-12-14 Io Biotech Aps Therapy
WO2024149237A1 (zh) 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987405A (zh) * 2011-11-28 2014-08-13 默克专利股份公司 抗pd-l1抗体及其用途
CN104334573A (zh) * 2012-04-30 2015-02-04 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
WO2015118175A2 (en) * 2014-02-10 2015-08-13 Merck Patent Gmbh TARGETED TGFβ INHIBITION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987405A (zh) * 2011-11-28 2014-08-13 默克专利股份公司 抗pd-l1抗体及其用途
CN104334573A (zh) * 2012-04-30 2015-02-04 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
WO2015118175A2 (en) * 2014-02-10 2015-08-13 Merck Patent Gmbh TARGETED TGFβ INHIBITION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSS STEWART等: "Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody", 《CANCER IMMUNOLOGY RESEARCH》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020248926A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗PDL1和TGFβ的双功能融合蛋白及其用途
US12325748B2 (en) 2019-06-10 2025-06-10 Shandong Boan Biotechnology Co., Ltd. Bifunctional fusion protein against PDL1 and TGFβ and use thereof
WO2021043229A1 (zh) * 2019-09-05 2021-03-11 复旦大学 靶向肿瘤的重组双功能融合蛋白及其应用
WO2021063350A1 (zh) * 2019-09-30 2021-04-08 和铂医药(苏州)有限公司 一种融合蛋白及其应用
WO2021115456A1 (en) * 2019-12-11 2021-06-17 Wuxi Biologics (Shanghai) Co., Ltd. BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ
CN115461362A (zh) * 2020-04-14 2022-12-09 葛兰素史密斯克莱知识产权发展有限公司 基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法
WO2022063193A1 (zh) * 2020-09-24 2022-03-31 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CN116323657A (zh) * 2020-09-24 2023-06-23 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CN116323657B (zh) * 2020-09-24 2023-12-08 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途

Also Published As

Publication number Publication date
IL264730B1 (en) 2024-05-01
JP7573365B2 (ja) 2024-10-25
EP3497130B1 (en) 2021-10-27
IL264730B2 (en) 2024-09-01
WO2018029367A1 (en) 2018-02-15
KR20190039200A (ko) 2019-04-10
US20180118832A1 (en) 2018-05-03
MX2019001503A (es) 2019-06-03
EP3497130A1 (en) 2019-06-19
CA3031168A1 (en) 2018-02-15
AU2017310027A1 (en) 2019-01-31
KR20250028537A (ko) 2025-02-28
CL2019000277A1 (es) 2019-07-05
SG11201901126UA (en) 2019-03-28
KR20230125859A (ko) 2023-08-29
PH12019500270A1 (en) 2019-07-01
RU2019106663A (ru) 2020-09-14
RU2019106663A3 (enExample) 2020-11-26
IL264730A (en) 2019-03-31
ES2905663T3 (es) 2022-04-11
US20220017621A1 (en) 2022-01-20
JP2019527706A (ja) 2019-10-03
BR112019001818A2 (pt) 2019-05-07
AU2024219446A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
CN109641963A (zh) 癌症的联合治疗
JP7716299B2 (ja) 小細胞肺癌に対する標的療法
US12065492B2 (en) Anti-B7-H6 antibody, fusion proteins, and methods of using the same
KR102569133B1 (ko) 삼중특이적 단백질 및 사용 방법
TWI715587B (zh) Ｔｉｇｉｔ結合劑和彼之用途
AU782994C (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
ES2782834T3 (es) Uso de moléculas inhibidoras de semaforina-4D en combinación con una terapia inmunomoduladora para inhibir el crecimiento tumoral y la metástasis
US20190365897A1 (en) Therapeutic compositions and related methods for photoimmunotherapy
US20180147257A1 (en) Btn3a ectodomain proteins and methods of use
KR20180081606A (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
JP2020528744A (ja) がん細胞を標的化するキメラ抗原受容体のための方法および組成物
KR20080099290A (ko) 암 치료용 ｉｌ-17 길항 항체
JP7459058B2 (ja) Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法
TW202003581A (zh) 對cd3具特異性之抗體及其用途
US20240010696A1 (en) IL-12 Variants and Uses Thereof
EP3896089A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
US20240239907A1 (en) C-X-C Motif Chemokine Receptor 6 (CXCR6) Binding Molecules, and Methods of Using the Same
HK40005313A (en) Combination therapy for cancer
KR20250086516A (ko) Il-12 변이체, 항-pd1 항체, 융합 단백질, 및 그의 용도
JP2025108362A (ja) Ｉｌ－１２バリアント、抗ｐｄ１抗体、融合タンパク質、およびその使用
CN115697374A (zh) 用于治疗胶质母细胞瘤的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005313

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190416

WD01 Invention patent application deemed withdrawn after publication